Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2043250110) titled 'A study to assess the long-term safety and clinical activity of mRNA-3927 in participants previously enrolled in the mRNA-3927-P101 study' on Oct. 7.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Kinoshita Masashi
Condition:
Propionic Acidemia
D056693
Intervention:
Patients enrolled in this long-term extension study will receive treatment using the same dosing regimen as in the mRNA-3927-P101 study (dose: 0.45 - 0.9 mg/kg), administered every 2 weeks, with a minimum dose of 0.45 mg/kg and not...